| Circos: an information aesthetic for comparative genomics M Krzywinski, J Schein, I Birol, J Connors, R Gascoyne, D Horsman, ... Genome research 19 (9), 1639-1645, 2009 | 10068 | 2009 |
| Revised response criteria for malignant lymphoma BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ... Journal of clinical oncology 25 (5), 579-586, 2007 | 5365 | 2007 |
| Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray CP Hans, DD Weisenburger, TC Greiner, RD Gascoyne, J Delabie, G Ott, ... Blood 103 (1), 275-282, 2004 | 5005 | 2004 |
| The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, ... New England Journal of Medicine 346 (25), 1937-1947, 2002 | 4823 | 2002 |
| Stromal gene signatures in large-B-cell lymphomas G Lenz, G Wright, SS Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, ... New England Journal of Medicine 359 (22), 2313-2323, 2008 | 2008 | 2008 |
| Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin RD Morin, NA Johnson, TM Severson, AJ Mungall, J An, R Goya, JE Paul, ... Nature genetics 42 (2), 181-185, 2010 | 1997 | 2010 |
| Genetics and pathogenesis of diffuse large B-cell lymphoma R Schmitz, GW Wright, DW Huang, CA Johnson, JD Phelan, JQ Wang, ... New England journal of medicine 378 (15), 1396-1407, 2018 | 1932 | 2018 |
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma RE Davis, VN Ngo, G Lenz, P Tolar, RM Young, PB Romesser, ... Nature 463 (7277), 88-92, 2010 | 1930 | 2010 |
| Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma RD Morin, M Mendez-Lago, AJ Mungall, R Goya, KL Mungall, RD Corbett, ... Nature 476 (7360), 298-303, 2011 | 1927 | 2011 |
| Oncogenically active MYD88 mutations in human lymphoma VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao, KH Lim, ... Nature 470 (7332), 115-119, 2011 | 1776 | 2011 |
| The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP LH Sehn, B Berry, M Chhanabhai, C Fitzgerald, K Gill, P Hoskins, R Klasa, ... Blood 109 (5), 1857-1861, 2007 | 1737 | 2007 |
| Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma TM Habermann, EA Weller, VA Morrison, RD Gascoyne, PA Cassileth, ... Journal of clinical oncology 24 (19), 3121-3127, 2006 | 1669 | 2006 |
| Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells SS Dave, G Wright, B Tan, A Rosenwald, RD Gascoyne, WC Chan, ... New England Journal of Medicine 351 (21), 2159-2169, 2004 | 1655 | 2004 |
| Tumor-associated macrophages and survival in classic Hodgkin's lymphoma C Steidl, T Lee, SP Shah, P Farinha, G Han, T Nayar, A Delaney, ... New England Journal of Medicine 362 (10), 875-885, 2010 | 1489 | 2010 |
| Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma A Rosenwald, G Wright, K Leroy, X Yu, P Gaulard, RD Gascoyne, ... The Journal of experimental medicine 198 (6), 851-862, 2003 | 1358 | 2003 |
| Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia LH Sehn, J Donaldson, M Chhanabhai, C Fitzgerald, K Gill, R Klasa, ... Journal of clinical oncology 23 (22), 5027-5033, 2005 | 1213 | 2005 |
| Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma MP Chao, AA Alizadeh, C Tang, JH Myklebust, B Varghese, S Gill, M Jan, ... Cell 142 (5), 699-713, 2010 | 1191 | 2010 |
| Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways G Lenz, GW Wright, NCT Emre, H Kohlhammer, SS Dave, RE Davis, ... Proceedings of the National Academy of Sciences 105 (36), 13520-13525, 2008 | 1179 | 2008 |
| Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone NA Johnson, GW Slack, KJ Savage, JM Connors, S Ben-Neriah, S Rogic, ... Journal of clinical oncology 30 (28), 3452-3459, 2012 | 1123 | 2012 |
| The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, ... Cancer cell 3 (2), 185-197, 2003 | 1089 | 2003 |
David W ScottClinician-Scientist, BC Cancer; Associate Professor, Department of Medicine, University of BritishVerified email at bccancer.bc.ca
